Watson Pharma intends to begin shipments of its generic version of Lidoderm in September 2013 per the terms of its settlement agreement with Endo. Watson believes it is entitled to a 180-day period of ...

An upstate New York pharmaceutical sales representative was among three whistle-blowers to supply information to federal prosecutors leading to a $193 million settlement with makers of the Lidoderm ...

SAN FRANCISCO (CN) - A federal judge on Thursday finalized two class action settlements worth $270 million, ending four years of litigation over an alleged antitrust conspiracy to keep a generic form ...

AUSTIN, TX—Arash Nafissi, DO, and colleagues of Hospital for Joint Disease, New York University, report that placing a topical Lidoderm patch provides an effective adjunct treatment in post-operative ...

Under the settlement agreement, the company inked a Deferred Prosecution Agreement (:DPA) with the United States Department of Justice. The duration of the DPA is up to 2 years and 6 months. In a ...

Endo Pharmaceuticals became the latest drugmaker to ink an off-label marketing settlement, paying $192.7 million to resolve charges it promoted pain patch Lidoderm for unapproved uses. According to a ...

SAN FRANCISCO (CN) – Rejecting arguments that damages would be too arduous to calculate on a class-wide basis, a federal judge this week certified two classes in a multidistrict antitrust suit over ...

PHILADELPHIA (Legal Newsline) – Endo Health Solutions Inc. and its subsidiary, Endo Pharmaceuticals, have agreed to a $171.9 million settlement with the federal government to resolve off-label ...

The US Department of Health and Human Services (HHS) has issued Endo Pharmaceuticals a subpoena regarding the promotion of its post-shingles pain patch Lidoderm. The subpoena requests documents from ...

Pharma has its latest pay-for-delay settlement. In a pair of deals with two plaintiff classes over generic Lidoderm delays, Endo, Teva and Japanese drugmaker Teikoku Seiyaku have agreed to fork over ...

SAN FRANCISCO (MarketWatch) -- Endo Pharmaceutical Holdings Inc. after Tuesday's closing bell said that the Food and Drug Administration's Office of Generic Drugs has issued bioequivalence ...

SAN FRANCISCO (MarketWatch) -- Endo Pharmaceuticals Holdings Inc. after Monday's closing bell said that net sales of Lidoderm, its largest-selling product, are expected to be below underlying demand ...